发明名称 |
Method For Predicting Responsiveness To Compound Inhibiting MAPK Signal Transduction Pathway |
摘要 |
Provided are: a method of predicting sensitivity to a molecularly targeted drug; a method of selecting a patient who is determined to have high responsiveness to administration of a drug; and a reagent to be used in these methods. Specifically, provided are: a method of predicting responsiveness to cancer disease treatment with a compound that inhibits a mitogen-activated protein kinase (hereinafter abbreviated as MAPK) signaling pathway, the method including using a biological sample derived from a cancer patient, measuring whether or not β-catenin contained in the biological sample has at least one kind of mutation selected from the group consisting of (i) an active mutation and (ii) a substitution mutation of an asparagine residue to a serine residue at position 287; a method of selecting a patient to be subjected to cancer disease treatment with the compound; a method of treating a cancer disease, the method including administering the compound to the patient selected by the above-mentioned method; and a reagent to be used in these methods. |
申请公布号 |
US2016011201(A1) |
申请公布日期 |
2016.01.14 |
申请号 |
US201414770474 |
申请日期 |
2014.02.27 |
申请人 |
DAIICHI SANKYO COMPANY, LIMITED |
发明人 |
KIGA Masaki |
分类号 |
G01N33/574;A61K31/4468;C12Q1/66 |
主分类号 |
G01N33/574 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of selecting a patient to be subjected to cancer disease treatment with a compound that inhibits a mitogen-activated protein kinase (hereinafter abbreviated as MAPK) signaling pathway, comprising:
using a biological sample derived from a cancer patient, measuring whether or not β-catenin contained in the biological sample has at least one kind of mutation selected from the group consisting of (i) an active mutation and (ii) a substitution mutation of an asparagine residue to a serine residue at position 287; and selecting a patient who is detected to have the mutation in β-catenin as a patient to be subjected to cancer disease treatment with a compound that inhibits a MAPK signaling pathway. |
地址 |
Tokyo JP |